We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
Molecular Medicine Reports 2012 January
Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro. However, there are no reports that Tan-IIA is capable of inhibiting J5 HCC cell growth in vivo. In this study, J5 cells were implanted directly into nude SCID mice which were divided randomly into four groups to be treated with vehicle, Tan-IIA (30 mg/-kg of body weight, Q.week days 3 and 5), 5-FU (30 mg/-kg of body weight, Q.week day 1) or Tan-IIA (30 mg/-kg of body weight, Q.week days 3 and 5) plus 5-FU (30 mg/-kg of body weight, Q.week day 1). Each agent was injected intraperitoneally, with treatment starting 4 weeks after inoculation with J5 cells. Treatment with Tan-IIA 30 mg/-kg or with 30 mg/-kg of 5‑FU resulted in a reduction in tumor size and weight compared with the control group. The protein expression of Bax and caspase-3 in the J5 xenograft tumors treated with Tan-IIA 30 mg/-kg or with 30 mg/kg of 5-FU was upregulated, whereas that of CD31 was downregulated compared with the control group. These findings indicate that Tan-IIA may inhibit tumor growth in a J5 xenograft animal model by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app